Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026

Syndax Pharmaceuticals (Nasdaq: SNDX) will host an in-person investor event and live webcast on December 14, 2026, during the ASH Annual Meeting.

Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq: SNDX) will host an in-person investor event and live webcast on December 14, 2026, during the ASH Annual Meeting.

The event runs from 7:00–8:30 a.m. CT / 8:00–9:30 a.m. ET. Management and medical opinion leaders will discuss data presented at the meeting. The webcast and a limited-time replay will be available in the Investor section of the company's website.

Argus 15 min delay 16 alerts

+0.63% vs previous close $14.38 last price 1.9x rel. volume Open Argus

Details

Market Reaction – SNDX

-9.0% Trough in 9 min

$13.00 – $14.91 Day Range

$1.28B Mkt Cap at Last Price

On Nov 4, the day this news came out, the latest delayed price for SNDX is 0.63% above the previous close. Argus tracked a trough of -9.0% from its starting point during tracking. Our momentum scanner has recorded 16 alerts for this stock so far that day. The latest delayed price is $14.38. Relative volume is above average at 1.9x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Terms

monoclonal antibody, csf-1 receptor

2 terms

monoclonal antibody medical

"an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

csf-1 receptor medical

"colony stimulating factor 1 (CSF-1) receptor"

A cell-surface protein found mainly on certain immune cells that acts like a lock for signaling molecules such as colony-stimulating factor 1; when those molecules bind, the receptor tells the cell to grow, move or change behavior. As a biological control point in inflammation, tissue repair and some cancers, it is a common drug target; investors watch drug candidates and clinical results involving the receptor because they can affect the commercial and regulatory prospects of biotech companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 14, 2026, from 7:00–8:30 a.m. CT / 8:00–9:30 a.m. ET during the 68^th American Society of Hematology (ASH) Annual Meeting. Members of the Syndax management team will be joined by multiple key opinion leaders to discuss key data presented at the ASH meeting.

A live webcast of the event will be available on the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contact

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G